1. Home
  2. PCLA vs NEUP Comparison

PCLA vs NEUP Comparison

Compare PCLA & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PicoCELA Inc. American Depositary Shares

PCLA

PicoCELA Inc. American Depositary Shares

HOLD

Current Price

$0.33

Market Cap

10.7M

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.98

Market Cap

10.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCLA
NEUP
Founded
2008
1996
Country
Japan
United States
Employees
N/A
N/A
Industry
Building Products
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
10.7M
10.3M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
PCLA
NEUP
Price
$0.33
$3.98
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
60.1M
76.0K
Earning Date
02-13-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,065,197.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.26
N/A
52 Week Low
$0.12
$3.00
52 Week High
$9.80
$21.40

Technical Indicators

Market Signals
Indicator
PCLA
NEUP
Relative Strength Index (RSI) 53.45 42.28
Support Level $0.29 $3.65
Resistance Level $0.35 $3.91
Average True Range (ATR) 0.08 0.19
MACD 0.01 0.10
Stochastic Oscillator 55.78 58.42

Price Performance

Historical Comparison
PCLA
NEUP

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: